"Omix" technologies: biochemical features of action neuro- and tissue-specific markers (review)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of research on modern analytical technologies, which are becoming more important. It is shown that an actively developing approach to early diagnosis of diseases is metabolomics, which studies the biochemical transformations of molecules in the cells of the body. Metabolomic studies based on nuclear magnetic resonance spectroscopy and mass spectrometry open up many opportunities for studying the complete metabolomic profile and especially its disorders resulting from adverse environmental factors or gene expression transformation (epigenetics). It is proved that the most common research methods in the framework of modern metabolomics are considered to be metabolic fingerprinting and metabolic profiling. The large possibilities of metabolomic profiling allow us to solve a significant number of fundamental and clinical problems.

Fundamental and clinical scientific data have demonstrated the feasibility of a multilateral study of the genesis and course of neurodegenerative disorders and cardiovascular diseases at the molecular level. Violation of metabolic pathways in certain organs and tissues can lead to significant changes in the composition of circulating peripheral blood metabolites or brain neurometabolites. Metabolism covers a wide range of biochemical reactions of the body and a diverse set of metabolites, therefore, pathological factors are able to change the metabolic profile of the body at different levels.

Analysis of domestic and foreign literature has shown that quantitative determination of lipids in biological samples (lipidomics) is considered equally important in metabolic profiling. This opens up great opportunities for the study of metabolic transformations of lipid molecules, as well as lipid-dependent mechanisms, which is extremely important for the study of neurodegenerative, neurological and neuropsychiatric disorders, since, depending on the associated biochemical pathways of the disease, lipids serve as potential marker molecules of these disorders and can be regarded as necessary diagnostic techniques.

The conclusion is formulated about the importance of studying metabolic disorders, a more detailed understanding of the pathogenetic mechanisms of the occurrence of diseases at the molecular level, the search for new marker molecules and additional factors leading to pathological conditions of the body.

Full Text

Restricted Access

About the authors

E. A. Teplyashina

Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky of the Ministry of Health of the Russian Federation

Author for correspondence.
Email: elenateplyashina@mail.ru

Ph.D. (Biol.), Associate Professor, Department of Biological Chemistry with a Course in Medical, Pharmaceutical and Toxicological Chemistry

Russian Federation, Krasnoyarsk

N. A. Malinovskaya

Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky of the Ministry of Health of the Russian Federation

Email: malinovskaya-na@mail.ru

Dr.Sc. (Med.), Head of the Department of Biological Chemistry with a Course in Medical, Pharmaceutical and Toxicological Chemistry

Russian Federation, Krasnoyarsk

L. B. Shadrina

Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky of the Ministry of Health of the Russian Federation

Email: shaliu@mail.ru

Assistant, Department of Biological Chemistry with a Course in Medical, Pharmaceutical and Toxicological Chemistry

Russian Federation, Krasnoyarsk

References

  1. Rutledge J., Oh H., Wyss-Coray T. Measuring biological age using omics data. Nature Reviews Genet. 2022; 23(12): 715–727.
  2. Patti G.J., Yanes O., Siuzdak G. Metabolomics: the apogee of the omic triology. Nature Reviews Molecular Cell Biology. 2012; 13: 4: 263–269.
  3. Au A., Cheng K.-K., Wei L.K. Metabolomics, lipidomics and pharmacometabolomics of human hypertension. Advances in experimental Medicine and Biology. 2016; 956: 599–613.
  4. Boccard J., Gonzalez-Ruiz V., Codesido S., Rudaz S. Mass spectrometry metabolomic data handling for biomarker discovery. Proteomic and Metabolomic Approaches to Biomarker Discovery. 2020; 369–388.
  5. Fiehn O. Metabolomics by gas chromatographymass spectrometry: Combined targeted and untargeted profil-ing. Curr. Protoc. Mol. Biol. 2016; 114(30): 1–30.
  6. Amoresano A., Pucci P. Mass spectrometry in metabolomics. Metabolomics Perspective. 2022; 109–147.
  7. Ortiz C., Carlen M., Meletis K. Spatial Trascriptomic: Molecular Maps of the Mammalian Brain. Annual Review of Neuroscience. 2021; 44: 547–562.
  8. Willsey H.R., Willsey A.J., Wang B., State M.W. Genomics, convergent neuroscience and progress in under-standing autism spectrum disorder. Nat Rev Neurosci. 2022; 23(6): 323–341.
  9. Korobkova E.O., Kozhevnikova M.V., Il'gisonis I.S. i dr. Metabolomnoe profilirovanie bol'nyx s metabolicheskim sindromom. Kardiologiya. 2020; 60(3): 37–43.
  10. Armand E.J., Li J., Xie F., Luo C., Mukamel E. Single-Cell Sequencing of Brain Cell Transcriptomes. Neuron. 2020; 109: 6: 11–26.
  11. Bai B., Wang X., Li Y., Chen P.-C., Yu K., Dey K.K. Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's Disease Progression. J. Nutr. 2020; 105(6): 9759–991.
  12. Sinclair E., Trivedi D.K., Sarkar D., WaltonDoyle C., Milne J., Rijs A.M., A de Bie R. M., Goodacre R., Silverdale M., Barran P. Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease. Int. J. Clin. Exp. Med. 2021; 12(1): 1592.
  13. Yang L., Lv P., Ai W., Li L., Shen S., Nie H., Shan Y., Bai Y., Huang Y., Liu H. Lipidomic analysis of plasma in patients with lacunar infarction using normal-phase/reversed-phase two-dimensional liquid chromatography–quadrupole time-of-flight mass spectrometry. Anal. Bioanal. Chem. 2017; 409: 3211–3222.
  14. Purroy F., Cambray S., Mauri-Capdevila G., Jove M., Sanahuja J., Farre J., Benabdelhak I., Molina-Seguin J., Colàs-Campàs L., Begue R. Metabolomics predicts neuroimaging characteristics of transient ischemic attack patients. EBioMedicine. 2016; 14: 131–138.
  15. Poupore N., Chosed R., Arce S., Rainer R., Goodwin R.L. Metabolomic Profiles of Men and Women Ischemic Stroke Patients. Talanta. 2021; 11(10): 1786.
  16. Hook V., Lietz C., Podvin S., Cajka T., Fiehn O. Diversity of Neuropeptide Cell-Cell Signaling Molecules Generated by Proteolytic Processing Revealed by Neuropeptidomics Mass Spectrometry. J Am Soc Mass Spectrom. 2018; 29(5): 807–816.
  17. Close J.L., Long B.R., Zeng H. Spatially resolved transcriptomic in neuroscience. Front. Mol. Neurosci. 2021; 18(1): 23–25.
  18. Gorina Ja.V., Komleva Ju.K., Lopatina O.L., Chernyh A.I., Salmina A.B. Vlijanie insulinorezistentnosti na narushenie metabolizma gljukozy v mindaline golovnogo mozga pri jeksperimental'noj bolezni Al'cgejmera. Bjulleten' sibirskoj mediciny. 2017; 16(4): 106–115.
  19. Komleva Ju.K., Gorina Ja.V., Chernyh A.I., Lopatina O.L., Shabalova A.A., Trufanova L.V., Olovjannikova R.Ja., Endrzheevskaja-Shurygina V.Ju., Salmina A.B. Osobennosti proliferacii i migracii kletok golovnogo mozga pri kognitivnom treninge zhivotnyh s jeksperimental'noj bolezn'ju Al'cgejmera. Sibirskoe medicinskoe obozrenie. 2016; 6: 1–5.
  20. Chen Q., Zhou T., Yuan J., Xiong X., Liu X., Qiu Z., Hu L., H. Lu, He Q., Liu C., Yang Q. Metabolomics profiling to characterize cerebral ischemia-reperfusion injury in mice. Front Pharmacol. 2023; 14: 1091616.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Figure. Levels of interaction between “omic” sciences. Original drawing created using Biorender.com software

Download (231KB)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies